-
Hengrui Medicine Launches Revelutamide for Metastatic Prostate Cancer in China
•
Hengrui Medicine has launched revelutamide (SHR3680; trade name: Erion), China’s homegrown innovative androgen receptor (AR) inhibitor, for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC) with high tumor burden. The drug received conditional market approval from the National Medical Products Administration (NMPA) in June 2022 and was first prescribed at…
-
Chongqing Lummy Pharma Cancels YZY Biopharma Y400 Partnership, Secures Compensation
•
China’s Chongqing Lummy Pharmaceutical Co., Ltd (SHE: 300006) announced the termination of its strategic partnership with Wuhan YZY Biopharma Co., Ltd, originally signed in September 2020. The deal granted Lummy exclusive priority sales rights to YZY Bio’s Y400, a bispecific antibody (BsAb) targeting VEGFA and ANG2, in Greater China. YZY…
-
HutchMed Initiates Phase I Study of CD47 Monoclonal Antibody HMPL-A83 in China
•
China-based HutchMed (NASDAQ: HCM, HKG: 0013) announced the initiation of a Phase I clinical study for HMPL-A83, its monoclonal antibody (mAb) targeting CD47, in patients with advanced malignant tumors. The first patient was dosed on July 15, 2022. Study DetailsThe multi-center, open-label Phase I trial (NCT05429008) will evaluate the safety,…
-
Grand Pharma Acquires Stake in Xeltis and Licenses aXess for Hemodialysis in Greater China
•
China-based Grand Pharmaceutical Group Limited (HKG: 0512) announced the acquisition of an 11% stake in Holland-based Xeltis AG, along with an exclusive license for the development, manufacturing, and commercialization of Xeltis’s endogenous tissue repair product aXess in Greater China. The deal, valued at €15 million ($15.2 million), grants Grand Pharma…
-
Fermion Secures Series B Financing to Advance AI-Driven Drug Development
•
Guangzhou-based AI biotech Fermion has raised over RMB100 million ($14.8 million) in a Series B financing round led by iFLYTEK Venture Capital, Zhengxuan Capital, Panda Capital, and Challenjers Venture Capital. The funds will advance its core drug pipelines, including a Phase I clinical study for FZ002, a chronic pain candidate,…
-
Biotree Raises $14.8M in Series A Financing to Expand Multi-Omics Platform
•
Shanghai-based multi-omics specialist Biotree has raised nearly RMB100 million ($14.8 million) in a Series A financing round led by Qiming Venture Partners. The funds will support platform expansion, R&D, production, and market promotion. Company BackgroundFounded in 2012, Biotree conducts metabolomic and proteomic research on human, animal, plant, and microbial samples.…
-
Kexing Pharmaceutical’s SHEN26 COVID-19 Drug Receives NMPA Approval for Clinical Trials
•
China-based Kexing Pharmaceutical (SHA: 688136) announced that its oral small-molecule COVID-19 drug SHEN26, co-developed with Shenzhen Antaiwei Biopharmaceutical Co., Ltd, has received approval from the National Medical Products Administration (NMPA) to proceed with clinical trials. Drug ProfileSHEN26 is a novel coronavirus polymerase (RdRp) inhibitor that blocks viral nucleic acid synthesis.…
-
WeDoctor Partners with Jinan Innovation Zone to Launch Dual Healthcare Platform
•
China-based WeDoctor Holdings Ltd, a Tencent-backed online medical service platform, has partnered with Jinan Innovation Zone to establish a dual-platform system combining an Internet health platform and an Internet traditional Chinese medicine (TCM) exchange platform. The collaboration builds on a previous provincial Internet health service platform focused on TCM digital…
